Pfizer (NYSE: PFE) has been around for 175 years, but the company's revenue soared to its highest ever only in more recent ...

Albert Bourla, Pfizer CEO, joins CNBC's Angelica Peebles and 'Closing Bell Overtime' to talk the impact of tariffs, Pfizer's drug pipeline, vaccines and more.

Pfizer Inc. is vulnerable to the possibility that President Donald Trump will place tariffs on the European Union, where the ...

Medicare changes will cut $1 billion from 2025 revenue, with Pfizer now responsible for 20% of catastrophic drug costs. Read ...

Pfizer faces revenue decline from patent expirations, profitability challenges, and bearish technicals. Learn why PFE stock ...

All this negativity, however, does open up an opportunity for investors to buy the stock at a discount. Despite being a top ...

Drugmaker Pfizer posted a better-than-expected fourth-quarter profit on Thursday, helped by cost cuts it began last year as it aims to show investors steadier execution and growth after large swings ...

Large American pharmaceutical companies are showing a distinct trend never seen before: they are increasingly looking for ...

Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range ...

Pfizer hopes a unique life-extension benefit for its Talzenna can serve to further expand the drug’s already ...